| Literature DB >> 30041434 |
Enamul Haque1,2, Alister C Ward3,4.
Abstract
Nanoparticles are increasingly being developed for in vivo use, from targeted drug delivery to diagnostics, where they have enormous potential, while they are also being used for a variety of applications that can result in environmental exposure for humans. Understanding how specific nanoparticles interact with cells and cell systems is essential to gauge their safety with respect to either clinical or environmental exposure. Zebrafish is being increasingly employed as a model to evaluate nanoparticle biocompatibility. This review describes this model and how it can be used to assess nanoparticle toxicity at multiple levels, including mortality, teratogenicity, immunotoxicity, genotoxicity, as well as alterations in reproduction, behavior and a range of other physiological readouts. This review also provides an overview of studies using this model to assess the toxicity of metal, metal oxide and carbon-based nanoparticles. It is anticipated that this information will inform research aimed at developing biocompatible nanoparticles for a range of uses.Entities:
Keywords: biocompatibility; nanoparticles; nanotoxicity; zebrafish
Year: 2018 PMID: 30041434 PMCID: PMC6071110 DOI: 10.3390/nano8070561
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Toxicological studies performed in zebrafish. Schematic representation of zebrafish development, from spawning of embryos through their rapid development and hatching into free-swimming larvae and further growth and development into adults. Nanoparticles (NPs) can be administered via a variety of routes, including injection into eggs or specific sites on juveniles and adults, or alternatively administered in the water, sediment or food. The key assays used to examine toxicity in this model are indicated.
LC50 toxicity testing in zebrafish embryos and adults of nanoparticles detailed in this review and selected others.
| Nano Particle | Stage | LC50 (mg/L) | Time | Teratogenicity | Reference |
|---|---|---|---|---|---|
| Cu | eggs | 24.0 | 48 h | Malformations, delayed hatching | [ |
| adults | 4.2 | 48 h | N/A | [ | |
| 1.5 | 48 h | N/A | [ | ||
| Chitosan | eggs | 280 | 96 h | Malformations | [ |
| Au | eggs | >200 | 48 h | None | [ |
| adults | >200 | 48 h | N/A | [ | |
| Ag | eggs | 2.7 | 48 h | Malformations | [ |
| 1.2 | 96 h | Malformations | [ | ||
| adults | 2.9 | 48 h | N/A | [ | |
| Cd/Te QDs | eggs | 186 (nM) | 120 h | Malformations, delayed hatching | [ |
| TiO2 | eggs | >1600 | 48 h | Premature hatching | [ |
| adults | >1600 | 48 h | N/A | [ | |
| ZnO | eggs | 3.5−9.1 | 120 h | None | [ |
| 1.8 | 96 h | Delayed hatching | [ | ||
| MgO | eggs | >3200 | 48 h | None | [ |
| 428 | 96 h | Delayed hatching | [ | ||
| adults | 140 | 48 h | N/A | [ | |
| Fe2O3 | eggs | >1600 | 48 h | None | [ |
| adults | >1600 | 48 h | N/A | [ | |
| NiO | eggs | 1700 | 48 h | None | [ |
| adults | 760 | 48 h | N/A | [ | |
| 45 | 30 d | N/A | [ | ||
| CuO | eggs | 960 | 48 h | None | [ |
| 175 | 48 h | None | [ | ||
| adults | 400 | 48 h | N/A | [ | |
| Fullerene | eggs | >200 | 48 h | None | [ |
| 1.5 | 96 h | Reduced hatching | [ | ||
| adults | >200 | 48 h | N/A | [ | |
| CNTs | eggs | >200 | 48 h | None | [ |
| >360 | 96 h | None | [ | ||
| adults | >200 | 48 h | N/A | [ |
Figure 2Carbon nanodot-based drug delivery and tracking. Schematic representation showing conjugation of carbon nanodots with drug molecules, and subsequent excitation to generate agents that act simultaneously as fluorescence tracers and drug delivery vehicles.